Preparation & Measurement Guide

Tesamorelin 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tesamorelin 5mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size Tesamorelin 5mg
Preparation 1mL bacteriostatic water
Concentration 5mg/mL after preparation
Documented Convention 1.4mg once daily

1. Preparation and Measurement

Tesamorelin 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 1mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in the approved comparator formulation. Frequency: once daily.

Period Documented amount Measurement
Documented approved-drug comparator 1.4mg once daily 0.28mL / 28 units

Vial estimate: One 5mg vial contains approximately 3 documented-size administrations at 1.4mg.

Practical Notes

  • The table applies only to this vial prepared with exactly 1mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Tesamorelin 5mg vial.
  • 1mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tesamorelin is the active molecule in an approved prescription product for a specific indication. The current approved formulation uses a formulation-specific 1.4mg daily amount and preparation method.

The table uses that amount only as a comparator. A laboratory vial is not the approved product, and its preparation instructions must not be assumed equivalent to the prescription formulation.

Primary Research and Regulatory References

  1. FDA EGRIFTA SV prescribing information
  2. Tesamorelin randomized clinical trial

Research Materials

Review Tesamorelin 5mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: Tesamorelin 5mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.